As a result of improved treatment and patient survival, ophthalmic complications are now being seen with increasing frequency in AIDS, occurring in up to 75% of patients during the course of the disease. The eye may be involved by an AIDS-related microvasculopathy, which gives rise to cotton wool spots, and by opportunistic infections caused by a wide range of organisms, including cytomegalovirus, herpes simplex virus, varicelia zoster, Toxoplasma gondii, Mycobacterium avium-intracellulare, Treponema pallidum, Pneumocystis carinii and various fungal agents. Opportunistic infections may be the presenting sign of disseminated infection. The eye may also be involved by neoplasms such as Kaposi's sarcoma and lymphoma, and by intracranial disease. Ocular involvement may lead to blindness if untreated and prompt ophthalmological referral is essential. This article reviews the range of ocular diseases seen in HIV and AIDS, current therapeutic options and outcome.
Since it was first described in 1981, acquired immune deficiency syndrome (AIDS) has become a cause of major public health concern worldwide. With the increasing use of antiretroviral drugs, as well as improved prophylaxis and treatment of opportunistic infections (in particular, Pneumocystis carinii pneumonia), the survival of patients with AIDS has increased. As a result, other forms of opportunistic infection, including those involving the eye, are now being seen with increasing frequency.',2 Ocular complications can be seen in up to 75% of patients in the course of the disease and are potentially sightthreatening. Many of these complications were previously seen only rarely in general ophthalmic practice, but they now present a formidable challenge to the ophthalmologist. They may show an atypical clinical appearance, follow an unusual course, and not infrequently prove refractory to conventional treatment.
The ophthalmic manifestations of AIDS can be grouped into four main categories: microvascular disease, opportunistic infections, neoplasms, and the neuro-ophthalmic manifestations of intracranial disease (box 1). Ophthalmic disease may affect any part of the visual system, namely the ocular adnexae (eyelids and orbit), the anterior segment (conjunctiva, cornea and iris), the posterior segment (retina, choroid and vitreous) and the optic nerve and afferent pathways. An anatomical approach is useful in the understanding and assessment of visual loss (box 2).
Ocular adnexal disease KAPOSI'S SARCOMA
The ocular adnexae may be involved by neoplasms such as Kaposi's sarcoma or lymphoma. Ocular Kaposi's sarcoma usually presents as a red mass on the eyelid or in the conjunctiva of the lower fornix, where it is easily mistaken for a subconjunctival haemorrhage.34 Involvement of the orbit may give rise to proptosis and diplopia. Kaposi's sarcoma in AIDS tends to be more resistant to treatment than endemic Kaposi's sarcoma. Vinca alkaloids (principally vinblastine), daunorubicin and bleomycin are the most commonly used chemotherapeutic agents. The use of alpha-and beta-interferon has met with limited success. Radiotherapy on the other hand has been found to be both safe and effective in local palliation.3 OCULAR LYMPHOMA Lymphoma of the eyelids and of the orbit is generally of the high grade B-cell type or varieties similar to Burkitt's lymphoma. They present as lumps affecting the eyelids and the conjunctiva or arise deeper in the orbit, causing proptosis and diplopia.5 The vitreous and retina may also be involved by primary ocular lymphoma. Patients need to be investigated for systemic lymphoma with imaging and biopsy. Treatment is mainly in the form of chemotherapy and radiotherapy.
MOLLUSCUM CONTAGIOSUM Molluscum contagiosum, caused by a pox virus, may appear during the course of HIV infection. It is characterised by multiple small elevated eyelid nodules which have an umbilicated central core (figure 1). Ocular irriation may result from an associated follicular keratoconjunctivitis. Molluscum has a tendency to recur after surgical removal or cryotherapy. 6 Conjunctival and corneal disease CONJUNCTIVITIS 
Treatment of cytomegalovirus retinitis
Ganciclovir and foscarnet are the two main agents currently available for the treatment of CMV retinitis.'6"l7 As neither agent eliminates the virus from the eye, treatment needs to be life-long. Insertion of a long-term indwelling central venous catheter is required, since both agents are administered intravenously. Treatment consists of an induction course of two or three weeks, followed by a lower maintenance dose (box 4). Regular follow-up is essential. Relapses are common and necessitate treatment with a further induction dose.
Ganciclovir Ganciclovir is a guanine analogue which inhibits viral DNA replication. An induction course of 5 mg/kg twice daily for 14-21 days is followed by a maintenance dose of 5 mg/kg daily. The main side-effect of ganciclovir is bone marrow suppression, which occurs in up to 38% of patients.'6 Concurrent zidovudine therapy may therefore be difficult. Treatment often has to be suspended if the neutrophil count falls below 500/mm3. However, the introduction of granulocyte growth factors such as Sargramostim (granulocyte-monocyte colony-stimulating factor) and Filgrastim (granulocyte colony-stimulating factor) and the use of alternative antiretroviral agents (eg, dideoxyinosine) has improved the outlook for many patients.'8",9
Foscarnet Foscarnet is a pyrophosphate analogue that inhibits DNA polymerase of cytomegalovirus. It also has some antiretroviral activity. As bone marrow suppression is much less marked, concurrent use of zidovudine is possible. It is given as an induction dose of 90 mg/kg bid for two to three weeks followed by a maintenance dose of 120 mg/kg once daily. The main side-effect of foscarnet is nephrotoxicity, and although this can be minimised by pretreatment with saline loading, it often requires the patient to switch to ganciclovir. Patients may develop further intolerance to foscarnet in the form of seizures and electrolyte abnormalities (hypocalcaemia, hypokalaemia, hypomagnesaemia and hypophosphataemia). Compared with ganciclovir, patients on foscarnet are also more likely to develop infusion-related symptoms (such as nausea and parasthesia) and genito-urinary ulcers. 20 Ganciclovir vsfoscarnet A multicentre controlled trial conducted by the Studies of the Ocular Complications of AIDS Research Group in collaboration with the AIDS Clinical Trials Group to compare ganciclovir with foscarnet has shown similar efficacies for the two drugs in terms of end-points such as interval to first reactivation and progression (56 days in the ganciclovir group and 59 days in the foscarnet group) as well as visual acuity. However, patients on foscarnet were found to have a median survival of 12.6 months, compared to 8.5 months for those on ganciclovir." While it is possible that the differences in survival were related to the intrinsic antiretroviral activity of foscarnet or to the fact that patients on ganciclovir were less able to tolerate zidovudine, the Policy and Data Monitoring Board recommended suspension of the treatment protocol after 19 months. Patients on foscarnet, however, were more likely to switch treatment as a result of toxic side-effects. The choice of treatment needs to be made ultimately on an individual basis, taking into account the patient's tolerance and motivation.
Intravitreal ganciclovir Intravitreal ganciclovir has been advocated for patients unable to tolerate systemic treatment, either because of toxicity or infusion- vitreous haze related problems. Recent interest has centred on a sustained-release device that maintains high levels of the drug in the eye.22 However, this option must be weighed against its potential disadvantages, which include the risk of endophthalmitis and retinal detachment as well as the loss of prophylaxis against disease elsewhere in the gastrointestinal tract, central nervous system and in the other eye.
Oral ganciclovir An oral preparation of ganciclovir has recently become available and has the advantage of avoiding the problems associated with the use of an intravenous catheter. Oral ganciclovir is, however, limited by poorer bioavailability. The lower serum levels achieved may make viral resistance more likely and lead to earlier relapse. It may find a future role as a prophylactic agent. 2 Other treatment options Retinal detachment may complicate the later stages of CMV retinopathy. Whilst surgery may be successful in achieving retinal reattachment, visual outcome has been disappointing owing to optic nerve disease and retinal damage. Laser photocoagulation to create a barrier chorioretinal scar has not been found to be effective in preventing progression of CMV retinitis. It may, however, find a role as treatment or prophylaxis for retinal detachment. Patients who develop a relapse of CMV retinitis have traditionally been treated with a further induction course of either ganciclovir or foscarnet. The Cytomegalovirus Retreatment Trial has shown combination therapy to be more effective than monotherapy in controlling recurrent disease.2' Several drugs are also presently under investigation. Cidofovir has a broad spectrum activity against herpes viruses but is limited by renal toxicity. ISIS 2922, given intravitreally, inhibits the messenger RNA of CMV. A monoclonal CMV antibody is also currently undergoing trials as adjunctive therapy.2
ACUTE RETINAL NECROSIS
Acute retinal necrosis is a rare necrotising retinitis typically affecting healthy immunocompetent individuals of any age, but is now also seen in patients with AIDS. It is caused by viruses of the herpes group, most commonly the varicella zoster virus but also the herpes simplex virus and CMV.24 Patients may give a history of recent cutaneous zoster and complain of peri-orbital pain and blurred vision. Unlike CMV retinitis, intense inflammation is a common feature. Fundal changes include sheathing of arterioles with minimal haemorrhages and multiple yellow-white retinal lesions which become confluent and progress to full thickness necrotising retinitis. The disease becomes bilateral in 40% of cases. Systemic acyclovir or ganciclovir have been used to arrest the disease process, but the overall prognosis is poor, especially if there is an associated retinal detachment.12 OCULAR TOXOPLASMOSIS Toxoplasma gondii is a common opportunistic pathogen in AIDS patients and it affects many organs, particularly the central nervous system and, less commonly, the eye.25 In healthy individuals, ocular toxoplasmosis is the commonest cause of posterior uveitis, occurring as a result of reactivation of encysted organisms following intra-uterine infection. Retinal lesions appear as white infiltrates which later take the appearance of pigmented scars as the inflammation subsides (figure 4). A vitritis is common, and gives rise to a vitreous haze or in severe cases to a 'headlight in the fog' appearance. In AIDS, the disease is unusual in many ways. Bilateral involvement is common, with the appearance of multifocal lesions that are not adjacent to old scars (box 3). These may therefore represent cases of newly acquired toxoplasmosis rather than reactivation. The organism also appears to affect both the retina and the choroid. 2 
Neuro-ophthahmic manifestations
Clinical evidence of intracranial disease is seen in up to 39% of AIDS sufferers.32 The central nervous system may be affected by neoplasms such as lymphoma and Kaposi's sarcoma or by opportunistic infections causing encephalitis, meningitis or cerebral abscess. Cranial nerve palsies occur as a result of raised intracranial pressure or secondary to an inflammatory or neoplastic neuropathy. They are most commonly associated with herpes zoster ophthalmicus, cryptococcal infection and lymphoma. Diplopia or pupillary abnormalities may be the first sign of serious intracranial disease. Gaze palsies and internuclear ophthalmoplegia have been seen in association with HIV encephalopathy, syphilis and toxoplasmosis. Papilloedema, optic neuritis, optic atrophy and visual field defects have also been described in relation to nervous system involvement by neoplasms or opportunistic infections.
Conclusion
The incidence of ocular disease in AIDS is likely to increase in the future as a result of improved patient survival. Ocular involvement may be the first indication of disseminated opportunistic infection. Moreover, the threat of sight loss is a major fear among AIDS sufferers. Early diagnosis and treatment of ocular complications are important to improve the quality of life. This requires a multidisciplinary approach to the management of AIDS and ophthalmological referral should be made at an early stage if ocular involvement is suspected.
